All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @dr.pablomonert on TikTok · 174s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @dr.pablomonert's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00and to make those decisions,
  2. 0:02they will succeed in doing this.
  3. 0:04And this is a way to help them
  4. 0:07to make them come to the school of America,
  5. 0:09and to make them look better,
  6. 0:11in the way they would prepare.
  7. 0:13So I always think it's something that's just
  8. 0:15a way to help them go.
  9. 0:17If you want to make them come to the school of America,
  10. 0:21then you'll have a lot of money,
  11. 0:22so for example,
  12. 0:23you can go and enter the school.
  13. 0:25And of course,
  14. 0:25you can make a money budget to make it run.
  15. 1:29to the extent of the looking,
  16. 1:31the uniform of water,
  17. 1:32and the climate to the extent of producing
  18. 1:36water, also is the best.
  19. 1:39It is the best way to make the country
  20. 1:43and make the country,
  21. 1:45and make the country.
  22. 1:47It is the best way to make the country
  23. 1:51the best way to make the world.
  24. 1:54The first place that has hit you in order to control the history of the country,
  25. 1:59and that is all that happened to your country.
  26. 2:04So, thank you for your benefit to be here,
  27. 2:09I hope you will enjoy the day and the day and the March of 2020,
  28. 2:13but tonight we are going to be doing our best to continue on the night,
  29. 2:17and to have a feeling of offering you a good evening,

Saxenda for weight loss: separating real results from TikTok hype

Dr Pablo Monert MD FACS.

TikTok creator

1.9M viewsWatch on TikTok

Quick answer

The video is captioned as an explainer on Saxenda (liraglutide 3.0 mg) for weight loss, a GLP-1 receptor agonist with FDA approval for chronic weight management in qualifying adults. However, the spoken transcript contains no clinical information about liraglutide's mechanism, patient selection criteria, or evidence base. No medical claims can be verified or refuted from the audio content as transcribed.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Saxenda for weight loss: separating real results from TikTok hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Saxenda for weight loss: separating real results from TikTok hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Saxenda for weight loss: separating real results from TikTok hype" from Dr Pablo Monert MD FACS.. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video is captioned as an explainer on Saxenda (liraglutide 3.

The reason this review is not generic is the source wording and the canonical claim label "glp1 saxenda para bajar de peso drpablomonert foryou parati saxen." In this clip, the useful excerpt is: "and to make those decisions, they will succeed in doing this." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Saxenda (liraglutide 3.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video is captioned as an explainer on Saxenda (liraglutide 3.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video is captioned as an explainer on Saxenda (liraglutide 3.0 mg) for weight loss, a GLP-1 receptor agonist with FDA approval for chronic weight management in qualifying adults. However, the spoken transcript contains no clinical information about liraglutide's mechanism, patient selection criteria, or evidence base. No medical claims can be verified or refuted from the audio content as transcribed.
  • The spoken transcript of this 1.9M-view video contains no verifiable medical claims about Saxenda. The caption and audio are mismatched.
  • Saxenda (liraglutide 3.0 mg) produced an average 8.4 kg greater weight loss than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), but about 37% of participants did not reach even 5% weight loss.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The spoken transcript of this 1.9M-view video contains no verifiable medical claims about Saxenda. The caption and audio are mismatched.
  • Saxenda (liraglutide 3.0 mg) produced an average 8.4 kg greater weight loss than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), but about 37% of participants did not reach even 5% weight loss.
  • Newer GLP-1 agents outperform liraglutide on weight outcomes. Tirzepatide showed average reductions above 20% body weight in SURMOUNT-1 (Jastreboff et al., 2022, NEJM). Saxenda remains approved and useful, but the field has moved.
  • Weight regain after stopping liraglutide is well-documented. This is a long-term treatment requiring ongoing clinician oversight, not a short course.
  • Saxenda carries a boxed warning for thyroid C-cell tumors in rodent studies and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
  • A medical professional's social media brand does not substitute for a clinical consultation. Prescription GLP-1 medications require individualized assessment before use.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @dr.pablomonert actually say?

Honestly? Very little about Saxenda. The transcript of this 1.9-million-view video is a jumbled, largely incoherent string of phrases about schools, money, water, and country-building. There is no discernible medical claim, dosing information, or clinical explanation of how liraglutide works. The video is captioned about Saxenda for weight loss, but the spoken content does not match that topic in any meaningful way.

This creates an immediate problem for fact-checking. The caption promises information about a regulated GLP-1 receptor agonist used in obesity treatment. The actual audio delivers something closer to a disconnected speech fragment. Viewers drawn in by the hashtags "saxenda" and "obesidad" are not getting what the packaging implies. That gap between caption and content is itself a credibility issue, regardless of the creator's intent.

Does the science back this up?

Since no specific medical claims were made in the transcript, there is nothing to verify against the literature. However, the topic the video was supposed to address, Saxenda and weight loss, is an area with a solid evidence base worth reviewing.

Saxenda (liraglutide 3.0 mg) is a GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that participants on liraglutide lost an average of 8.4 kg more than those on placebo over 56 weeks. That is meaningful but not transformative compared to newer agents. Tirzepatide, for context, showed average weight reductions above 20% in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Liraglutide works, but it is no longer the most effective option in its class.

What did they get wrong (or right)?

There is nothing to label right or wrong in the clinical sense because no clinical content was delivered. What the creator got wrong is the basic responsibility of producing coherent health content under a medical professional's brand. A video captioned with a prescription medication name, posted by an account presenting as a physician, carries an implicit promise of accuracy and usefulness.

The hashtag "drpablomonert" and the medical facility tag "torremedicasanandres" suggest this is positioned as professional medical commentary. When a video wearing that label delivers no actual information about the drug in question, it is not neutral. It can drive viewers to search for Saxenda information elsewhere, potentially landing on far worse sources. The absence of misinformation is not the same as the presence of responsible communication.

What should you actually know?

If you found this video searching for information about Saxenda, here is what the video did not tell you.

  • Saxenda requires a prescription and should only be used under supervision of a licensed clinician who has reviewed your full medical history.
  • Common side effects include nausea, vomiting, diarrhea, and constipation, particularly in the first weeks of use. These are dose-dependent (Davies et al., 2015, The Lancet).
  • Saxenda is not appropriate for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Weight loss results vary substantially. The SCALE trial showed about 63% of participants achieved at least 5% weight loss, meaning roughly 37% did not hit that threshold.
  • Stopping Saxenda is associated with weight regain. It is a chronic treatment, not a short-term fix, and decisions about duration should be made with a clinician.

Anyone making treatment decisions based on a TikTok caption is working with incomplete information. That applies here more than most.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Pablo Monert MD FACS. · TikTok creator

1.9M views on this video

SAXENDA PARA BAJAR DE PESO. #drpablomonert #foryou #parati #saxenda #santosomingodelostsachilas #torremedicasanandres #obesidad #cambiodevida

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the spoken transcript of this 1.9m-view video contains no verifiable?

The spoken transcript of this 1.9M-view video contains no verifiable medical claims about Saxenda. The caption and audio are mismatched.

What does the video say about saxenda (liraglutide 3.0 mg) produced an average 8.4 kg greater?

Saxenda (liraglutide 3.0 mg) produced an average 8.4 kg greater weight loss than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), but about 37% of participants did not reach even 5% weight loss.

What does the video say about newer glp-1 agents outperform liraglutide on weight outcomes. tirzepatide showed?

Newer GLP-1 agents outperform liraglutide on weight outcomes. Tirzepatide showed average reductions above 20% body weight in SURMOUNT-1 (Jastreboff et al., 2022, NEJM). Saxenda remains approved and useful, but the field has moved.

What does the video say about weight regain after stopping liraglutide?

Weight regain after stopping liraglutide is well-documented. This is a long-term treatment requiring ongoing clinician oversight, not a short course.

What does the video say about saxenda carries a boxed warning for thyroid c-cell tumors in?

Saxenda carries a boxed warning for thyroid C-cell tumors in rodent studies and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

What does the video say about a medical professional's social media brand does not substitute for?

A medical professional's social media brand does not substitute for a clinical consultation. Prescription GLP-1 medications require individualized assessment before use.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Pablo Monert MD FACS., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.